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Abstract
Background: Disease management programmes (DMPs) have been shown to reduce hospital readmissions and
mortality in adults with heart failure (HF), but their effectiveness in elderly patients or in those with major
comorbidity is unknown. The Multicenter Randomised Trial of a Heart Failure Management Programme among
Geriatric Patients (HF-Geriatrics) assesses the effectiveness of a DMP in elderly patients with HF and major
comorbidity.
Methods/Design: Clinical trial in 700 patients aged ≥ 75 years admitted with a primary diagnosis of HF in the
acute care unit of eight geriatric services in Spain. Each patient should meet at least one of the following
comorbidty criteria: Charlson index ≥ 3, dependence in ≥ 2 activities of daily living, treatment with ≥ 5 drugs,
active treatment for ≥ 3 diseases, recent emergency hospitalization, severe visual or hearing loss, cognitive
impairment, Parkinson’s disease, diabetes mellitus, chronic obstructive pulmonary disease (COPD), anaemia, or
constitutional syndrome. Half of the patients will be randomly assigned to a 1-year DMP led by a case manager
and the other half to usual care. The DMP consists of an educational programme for patients and caregivers on
the management of HF, COPD (knowledge of the disease, smoking cessation, immunizations, use of inhaled
medication, recognition of exacerbations), diabetes (knowledge of the disease, symptoms of hyperglycaemia and
hypoglycaemia, self-adjustment of insulin, foot care) and depression (knowledge of the disease, diagnosis and
treatment). It also includes close monitoring of the symptoms of decompensation and optimisation of treatment
compliance. The main outcome variables are quality of life, hospital readmissions, and overall mortality during a 12-
month follow-up.
Discussion: The physiological changes, lower life expectancy, comorbidity and low health literacy associated with
aging may influence the effectiveness of DMPs in HF. The HF-Geriatrics study will provide direct evidence on the
effect of a DMP in elderly patients with HF and high comorbidty, and will reduce the need to extrapolate the
results of clinical trials in adults to elderly patients.
Trial registration: (ClinicalTrials.gov number, NCT01076465).
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Background
Ninety percent of persons with incident heart failure
(HF) are age 65 or over; moreover, the prevalence of HF
increases with age, rising from 5-10% in persons aged
65-79 years to 10-20% in those 80 years or over [1]. In
Spain, about 500,000 persons over the age of 60 suffer
from HF [2]. HF is the most frequent reason for hospital
admission and readmission [3] and is the third leading
cause of cardiovascular death in the elderly [4]. More-
over, it represents about 2% of total health costs [5].
The number of hospitalisations for HF is expected to
increase up to 50% in the next 20 years [6].
HF produces physical and cognitive impairment as
well as reduced quality of life [7-9]. Annual mortality
exceeds 50% in patients with New York Heart Associa-
tion (NYHA) classes III and IV [10]. Advanced age, as
well as low quality of life and poor social network - two
variables which are not routinely assessed in patients -
are all associated with a higher risk of hospitalisation
and death in HF [11,12].
Treatments are available to modify the course of HF
with left ventricular systolic dysfunction (LVSD) [13,14],
but they have not managed to significantly reduce mor-
tality and hospital readmission in routine clinical prac-
tice [15,16]. The prognosis for HF with preserved
systolic function is similar to that of HF with depressed
ejection fraction, but there is no evidence of effective
treatments in the latter group, and clinical practice
guidelines offer few specific recommendations for its
treatment. The current therapeutic approach for these
patients is symptomatic treatment, together with control
of cardiovascular risk factors and heart rate [13,14].
Management of HF
There is good evidence in patients with HF and high
risk of hospitalisation that multidisciplinary strategies
based on coordination and continuity of care can reduce
mortality by 25%, hospital admissions for HF by 26-44%,
and admissions for any cause by 19-27%, without
increasing length of stay [17]. Thus, implementation of
these disease management programmes (DMPs) is
recommended in the major clinical practice guidelines
[13,14]. In these DMPs a case manager provides patients
and their caregivers with sufficient information and sup-
port to develop and comply with a plan to control HF.
The case managers also reinforce compliance with treat-
ment and detect early signs of HF decompensation.
In Spain, several DMPs have been evaluated in elderly
HF patients. Morcillo et al. randomised 70 patients with
severe HF and major systolic dysfunction (NYHA III or
IV and left ventricular ejection fraction < 35%), previous
hospitalisation for HF and mean age 79.1 years to “usual
care” versus intervention by a case manager. At 6
months follow-up there were fewer deaths, emergency
department visits and hospital readmissions in the inter-
vention group [18]. However, the exclusion criteria were
very strict, so that these patients may not be representa-
tive of many patients with HF. Atienza et al., in a rando-
mised trial in 338 patients with a mean age of 68 years,
showed that a DMP in tertiary hospitals can reduce
readmissions for HF by 30% [19]. Lupón et al. obtained
a 49% reduction in admission of patients with HF after
1 year of applying a HF programme (non-randomised
before-and-after analysis) [20]. Brotons et al. recently
reported a randomised home-based intervention study
in 283 patients with a mean age of 76 years, 89% of
whom had NYHA class III-IV HF. They observed a con-
siderable reduction in the combined endpoint readmis-
sion or death at 1-year follow-up; however, only 25% of
the patients initially evaluated could be included because
the rest either did not meet the selection criteria or
refused to participate [21].
HF management programmes in patients with advanced
age and major comorbidity
The mean age of patients included in studies that have
evaluated the effectiveness of DMPs in HF is 73 years,
which is substantially lower than that of patients hospi-
talised for HF in geriatric services [22]. Most clinical
trials in HF have excluded elderly (75-85 years) and very
elderly (> 85 years) patients with significant functional
impairment, polymedication, physical comorbidity, and
preserved ventricular function. This is important
because 95% of elderly HF patients have non-cardiac
conditions that make their clinical management difficult
and lead to increased mortality [23]. Furthermore, the
process and structure of DMPs in HF vary widely, there-
fore it is difficult to identify which specific interventions
account for their benefits [23].
For all these reasons, we do not know the effectiveness
of DMPs or of their main components in geriatric
patients with HF. Specifically, it is unclear whether sys-
tematic assessment and intervention on psychosocial
factors can improve these patients’ vital prognosis and
quality of life. It is particularly important to test whether
interventions useful in younger HF patients are also use-
ful in elderly patients with predominantly preserved sys-
tolic function and some level of comorbidity [24].
Finally, little information is available on the long-term
outcomes of DMPs in HF. Although the effects are
maintained up to 6 months [25], it has also been
observed that interruption of DMPs is accompanied by
loss of their effect [26]. Thus, future evaluations of
DMPs should cover a minimum period of 1 year.
Study objectives
The main objective of the HF-GERIATRICS study is to
assess the effectiveness of a DMP in elderly patients
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with HF and major comorbidity over 12 months. Effec-
tiveness will be based upon hospital readmission, health-
related quality of life, and mortality from any cause.
The secondary objectives are to assess the impact of
the DMP on some intermediate variables such as knowl-
edge of the disease by patients and family members, and
improved HF care, which includes compliance with
recommendations on lifestyles and drug treatment. This
study also aims to measure the impact of the DMP on
length of hospital readmissions and to identify the clini-
cal, demographic and psychosocial characteristics of
patients who benefit most from the DMP.
Methods/Design
Design
The HF-GERIATRICS study is a trial in elderly patients
who are admitted with a primary diagnosis of HF in
acute care units of eight geriatric services in Spain.
Patients are assigned randomly to a DMP (intervention
group) or to receive usual care (control group). Rando-
misation is stratified by hospital and is conducted with
concealment of the randomisation list. The two trial
groups are followed for 12 months.
The project has been approved by the clinical research
ethics committee of all participating hospitals (Comité
de Etica y Ensayos Clínicos (CEIC) de Galicia, CEIC del
Complejo Hospitalario de Caceres, CEIC del Hospital
Universitario La Paz, CEIC del Complejo Universitario
de Albacete, CEIC del Hospital Universitario de Guada-
lajara, CEIC del Hospital Central de Asturias, CEIC del
Hospital Universitario de Getafe, CEIC del Hospital Uni-
versitario de San Carlos, Spain).
Study participants
The study will include patients aged 75 years or over who
are admitted with a primary diagnosis of HF according to
the European Society of Cardiology and Framingham cri-
teria [14,27]. Each patient must also meet at least one of
the following comorbidity criteria: Charlson index ≥ 3
(regardless of age), dependence in ≥ 2 basic activities of
daily living, prescription of ≥ 5 drugs, emergency hospita-
lisation in the last 3 months, active treatment for ≥ 3 dis-
eases, limitations in daily life due to visual or hearing
loss, cognitive impairment, Parkinson’s disease, diabetes
mellitus, chronic obstructive pulmonary disease (COPD),
anaemia or constitutional syndrome whose causes have
not been determined previously.
Exclusion criteria are terminal or rapidly fatal disease
and life expectancy of less than 6 weeks, severe func-
tional or cognitive impairment preventing patients from
understanding their illness and lack of a caregiver who
agrees to participate in the study, patients waiting for
cardiac surgery, those who cannot be followed up (e.g.,
due to change of address), and institutionalised persons
for whom a primary caregiver cannot be identified.
Identification of participants, informed consent and
randomisation
In each hospital a case manager with a degree in health
sciences and special training in HF will identify and reg-
ister cases admitted for HF each day by reviewing the
diagnoses of those aged ≥ 75 years admitted in the
acute care unit of the geriatric service. The case man-
ager will then assess each patient and carry out the fol-
lowing activities:
i- Verify the study inclusion and exclusion criteria.
ii- Inform patients (verbally and in writing) and their
caregivers (when considered necessary and with the
patient’s consent) of the characteristics of the DMP and
confirm their agreement to participate by asking them
to sign the informed consent document.
iii- Assign the patient to the intervention or control
group. Randomisation will be conducted independently
in each centre. Consecutively numbered envelopes, con-
taining the group to which each patient should be
assigned, will be used for this purpose. The envelope
will be opened only at the time of patient assignment,
to assure concealment of the randomisation list.
iv- Coordinate patient assessment, record the informa-
tion in the case report form, and transcribe the informa-
tion to a computerized database.
Description of the intervention: Disease Management
Programme
The DMP, which will be carried out by the case man-
ager, has three main components: education of the
patient and the main caregiver to improve disease
knowledge and self-management, monitoring of the
patient’s clinical condition, and monitoring of treatment
compliance.
a) DMP components to be conducted by the case
manager during the hospital stay
i- Provision of information to patients and their
caregivers or family members. An individual ses-
sion will be held to teach the characteristics,
causes and prognosis of HF. Emphasis will be
given to recognition of symptoms of decompen-
sation, precipitating factors, and treatment (drug
knowledge and treatment compliance).
ii- Provision of written and graphic educational
materials with the foregoing information.
iii- Health education on warning signs and symp-
toms and information on drugs for the most
common comorbidities: diabetes, COPD and
depression.
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iv- Coordination of hospital discharge with ward
nursing staff
v- Development of a follow-up plan. A date for
an outpatient appointment will be set, and a tele-
phone contact number will be provided to
patients so they can ask questions or report any
incidents.
b) Components of the DMP to be conducted by the
case manager after hospital discharge
The case manager will devote 2 days/week to the
clinical assessment of outpatients. The first contact
with the patient will be by telephone, in the second
week after hospital discharge: during this call, the
case manager will verify the patient’s knowledge of
HF, reinforce the information provided during hospi-
talisation, and strengthen compliance with recom-
mended lifestyles and pharmacological treatment.
Control of minor symptoms of decompensation by
use of diuretics will be emphasized. The first visit
will take place at the hospital outpatient clinic 4
weeks after discharge. Future visits will be agreed
according to the patient’s clinical and treatment
needs, but some minimum controls will be estab-
lished at months 1, 2, 3, 6, 8 and 12 after discharge
(table 1). The case manager will be provided with a
cell phone to facilitate coordination with patients,
caregivers and other health professionals. Messages
left with the case manager will be answered within
24 hours.
The DMP will be supervised by the geriatricians on
the research team, who will progressively delegate clini-
cal functions to the case manager. A training pro-
gramme for case managers will be conducted before the
beginning of the trial. The DMP includes protocols for
HF diagnosis and treatment will be implemented, based
on the clinical guidelines of the European Society of
Cardiology [14]. It also includes protocols to optimise
the diagnosis and treatment of COPD, diabetes mellitus
and depression. All cases of COPD are to be confirmed
by spirometry, and patients and their caregivers will be
trained on the use of inhaled drugs, smoking cessation,
use of vaccines, and identification and management of
exacerbations; in addition, treatment will be established
Table 1 Design and data collection in the HF-Geriatrics study
TIME CONTROL GROUP INTERVENTION GROUP WHO DOES IT
Admission Review of inclusion and exclusion criteria
Informed consent
Randomisation
BASELINE VARIABLES
Case manager
ROUTINE MEDICAL MONITORING
(will vary across centres)
Educational session
Knowledge of disease
Drugs
Comorbidity
Follow-up information
Plan for discharge
Questionnaires on self-care and disease knowledge for patient and caregiver
2 weeks Telephone contact
Symptoms-signs
Compliance
Next appointment
Case manager
1 month Consultation with case manager
Educational reinforcement
Drugs-Compliance
Comorbidity
Follow-up
Case manager
2 months Consultation with case manager Similar to above Case manager
3 months Consultation with case manager Similar to above Case manager
6 months Consultation with physician Physician
Consultation with case manager
Similar to above
Case manager
REGISTRY OF VARIABLES Research team
8 months Consultation with case manager Similar to above Case manager
12 months Consultation with physician Physician
Consultation with case manager
Similar to above
Case manager
REGISTRY OF VARIABLES Research team
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in accordance with the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) recommendations.
Patients with diabetes mellitus will receive an educa-
tional intervention on the symptoms of hypoglycaemia
and hyperglycaemia, foot care, and, for patients treated
with insulin, on the proper technique for its administra-
tion and self-monitoring of capillary blood glucose. In
cases of depression, a clinical assessment of the diagno-
sis will be made if the score on the 15-item Yessavage
test is > 5, and appropriate treatment will be initiated.
At outpatients clinic visits and telephone contacts,
case managers will identify warning signs and symptoms
of clinical deterioration from records of blood pressure
and heart rate, changes in body weight, night-time
cough, degree of dyspnea, decreased physical activity,
and biomarkers such as renal function, natriuretic pep-
tides and haemoglobin saturation by pulse oximetry.
For patients in the control group, the same intermedi-
ate and outcome variables will be recorded as in the
intervention group, but the previously described educa-
tional activities and monitoring by the case manager will
not be carried out. Follow-up will begin with the index
admission and ends 12 months after discharge or in
case of the patient’s death.
Study variables
In addition to the inclusion and exclusion criteria, four
types of variables will be collected: psychosocial, biome-
dical, treatment prescribed, and intermediate and final
outcome variables (table 2). Episodes of hospital emer-
gency care will also be recorded. The intermediate out-
come variables are knowledge of the nature and
management of HF and of comorbidity, and compliance
with recommendations on lifestyle and drug treatment.
Table 2 Data collected in the study
Type of data Variables
Definition of inclusion criteria Hospitalisation.- hospital stay at least one night.
Heart failure.- Framingham and European Society of Cardiology criteria
Comorbidity.- Charlson index and other (see text) [34]
Psychosocial variables *Sex
#Dependence in ADLs and IADLs.- Index of Katz [35] and Lawton [35,36]
#Quality of life.- Minnesota Living With Heart Failure Questionnaire [37]
#Depression.- 15-item Yessavage depression scale [38]
#Cognitive function.- Lobo cognitive miniexam [39]
#Health literacy.- SHALSA questionnaire[40]
#Knowledge of disease [33]
#Knowledge of treatment and self-care measures [41]
*Housing conditions [42]
*Social support.- OARS questionnaire [43]
#Treatment compliance.- interview and Morisky-Green test.
Biomedical variables *Age
*Pneumococcal and influenza vaccinations
*Cardiovascular risk factors.- hypertension, smoking, diabetes, hypercholesterolemia and obesity.
*Factors leading to admission
*Length of hospital stay
*Aetiology of heart failure
#Functional class (NYHA)
*Ejection fraction.- transthoracic echocardiography
#Blood sodium, NTpBNP, creatinine and glucose
#Blood pressure, height and weight (body mass index)
Treatment #Total number of drugs
#Drugs.- loop and potassium-sparing diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor
blockers, beta-blockers, antiplatelets, anticoagulants, statins
#Adverse effects associated with treatment
Number of emergency
department visits
#To be detected by review of the computerized clinical history or by the hospital admission records, counting all
episodes after the date of discharge of the index admission. The number of these visits directly related with heart
failure will be recorded.
Intermediate outcome variables #Knowledge of disease
#Self-care measures
Final outcome variables #Readmission.- all hospitalisation episodes of more than 24 hours following the date of discharge of the index
admission. The following variables will be recorded: number and proportion of patients who are readmitted,
number of readmissions per patient, and length of hospital stay during readmissions.
#Death.- To be determined by follow-up of each patient. This will be documented in the clinical history and the
mortality registries.
#Quality of life.- Measured by the Minnesota Living With Heart Failure Questionnaire
ADLs: Basic activities of daily living; IADLs: Instrumental activities of daily living; * Variables to be registered only during the index admission; # Variables to be
registered at the index admission and at 6 and 12 months.
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The final outcome variables are health-related quality of
life (assessed using the Minnesota Living with Heart
Failure Questionnaire [MLWHFQ]), hospital readmis-
sions, and total mortality. The outcome variables are
measured at 6 and 12 months after the DMP begins.
The information is collected through interview with the
patient or primary caregiver and review of the clinical
record.
Study size
In previous studies we observed that about 30% of HF
patients are readmitted every 6 months [11]. These stu-
dies were conducted in hospitals and with patient’s
inclusion criteria different from those in the HF-Geria-
trics, and within patients with less use of effective drug
treatments than at present. Accordingly, under the con-
servative assumption that the annual frequency of read-
mission will be 40%, and that the frequency of
readmission is similar in all study hospitals, 700 patients
will need to be recruited (350 in each group) to detect,
with an alpha error of 5% and a statistical power of
80%, a 20% reduction in hospital admission. This analy-
sis assumes, as can be expected, that no patients will be
lost to follow-up. A total of 700 patients also allows to
detect, with an alpha error of 5% and 80% power, differ-
ences of 10 points (clinically relevant) in the MLWHFQ,
assuming that patients in the control group have a
mean score of 50 points on this questionnaire [11].
Statistical analysis
We will first verify the effectiveness of randomisation.
The calculated sample size should be sufficient to assure
an even balance of the predictors of the outcome vari-
ables between the intervention and control groups.
Second, we will estimate the time to readmission or
death for each patient, and will obtain curves for time
free of such events (Kaplan-Meier method) in the inter-
vention and control groups. These curves will be com-
pared using univariate methods. The effectiveness of
DMP will be summarized with hazard ratios (and their
95% confidence intervals) for readmission and mortality
obtained by Cox regression, using the hospital as strati-
fication variable. Finally, if the DMP is shown to be
effective, we will estimate the number of patients needed
to treat (NNT) to prevent one outcome event.
For health-related quality of life, the MLWHFQ score
at baseline, 6 months and 12 months will be calculated
for each group in the trial. The effect of the DMP on
quality of life will be estimated as the difference between
groups in the change in MLWHFQ scores during the
study. These differences will be accompanied by their
respective 95% confidence intervals.
The analyses of the effect of DMP will be performed
according to the intention-to-treat principle.
Discussion
To our knowledge, this is the first evaluation of a DMP
in HF targeting elderly patients with major comorbidity.
Elderly patients should be included in evaluations of
DMPs because they have specific clinical characteristics.
First, the elderly have a lower life expectancy than
younger adults; thus, the interventions must be success-
ful in the short or medium term. In addition, their
health status is more heterogeneous, and the expecta-
tions and preferences of these patients are different
from what they were at younger ages. Second, the effect
of interventions on outcomes like quality of life and
functional status should receive as much attention as
the “hard” endpoints traditionally studied (e.g., hospital
readmission, mortality, etc.). Third, the prognostic
importance of comorbidity in the elderly is similar to or
even greater than that of HF itself. Thus, control of
comorbidity should be an important target of DMPs. In
other words, DMPs for HF in the elderly should “look
beyond the heart” [28]. Designing interventions for
patients with comorbidity is complex since we must
select those with the greatest possibility of success to
avoid overburdening patients with treatments of doubt-
ful therapeutic value. For this reason, the HF-Geriatrics
study has selected comorbidities for which there is good
evidence of the benefit of the intervention [29-32].
The main strengths of this study are random assign-
ment to the intervention, concealment of the randomi-
sation list, intention-to-treat analysis, and the very
nature of the DMP designed. This DMP follows the
recommendations of the major scientific societies in this
field (13,14) and has been refined through a literature
search for successful interventions. In addition, the
intervention will be adapted to the educational level and
visual limitations of most patients with the following
measures: a) selection of a limited number of self-care
skills to manage HF, COPD, diabetes mellitus and
depression, to identify the warning signs of decompensa-
tion, and to comply with treatment [33]; b) implementa-
tion of only two brief educational sessions, the first
during hospitalisation and the second on the day of dis-
charge, as well as a telephone call 15 days after dis-
charge; c) development of printed educational materials
with brief text and large print, avoiding technical terms
and with numerous explanatory pictures, to be given to
patients in the intervention group on the day of hospital
discharge; d) provision of a telephone contact number
to patients so they can ask questions or resolve any
issues they may have.
We plan to conduct specific training and certification
of the case managers in the coordinating centre and to
develop protocols for each of their activities. This
ensures that the same intervention will be applied simi-
larly in all participating centres and that, if the efficacy
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of the DMP is shown, it can easily be expanded to other
health care settings.
The main challenges of the project are recruitment of
study participants, avoidance of contamination of the
intervention between the two trial groups, and minimi-
zation of losses to follow-up. To ensure sufficient
recruitment, we have reviewed the basic hospital dis-
charge dataset for each participating hospital, and have
found that they each admit at least 100 patients with
the characteristics needed for the project every 6
months. To avoid contamination, the case manager will
conduct the DMP in a separate consultation, at a time
of day other than when patients usually receive care.
Finally, to minimize losses to follow-up, the intervention
will be brief and will include only a small number of
hospital visits. In addition, patient access to the case
manager will be facilitated (by telephone or in person)
so that any questions or problems that arise during the
intervention can be addressed.
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